圣诺生物：前三季度净利同比预增101%~145%

Core Viewpoint - Shengnuo Bio (688117.SH) expects a significant increase in net profit for the first three quarters of 2025, projecting a range of 114 million to 140 million yuan, representing a year-on-year growth of 100.53% to 145.10% [1] Group 1 - The company's main business is experiencing stable development, contributing to the overall performance improvement [1] - The construction of production capacity is gradually being realized, which supports the company's growth [1] - The demand for orders in the peptide raw material business continues to grow, enhancing the company's market competitiveness and sustainable profitability [1]